CHRS - Coherus Biosciences Inc
IEX Last Trade
1.39
-0.030 -2.158%
Share volume: 593,447
Last Updated: Fri 30 Aug 2024 09:57:45 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.42
-0.03
-2.11%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-08 | 2023-03-06 | 2023-05-08 | 2023-08-02 | 2023-11-06 | 2024-03-15 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 546.003 M | 550.907 M | 480.847 M | 402.426 M | 469.591 M | 583.783 M | 629.604 M | 763.545 M | |
| Current Assets | 446.784 M | 448.275 M | 381.234 M | 315.926 M | 385.484 M | 444.365 M | 475.631 M | 627.477 M | |
| Inventories | 31.744 M | 27.719 M | 38.791 M | 49.406 M | 63.989 M | 66.783 M | 62.605 M | 61.978 M | |
| Other Current Assets | 23.845 M | 42.565 M | 40.798 M | 36.973 M | 35.475 M | 29.994 M | 34.756 M | 21.579 M | |
| Short Term Investments | 23.845 M | 42.565 M | 40.798 M | 36.973 M | 35.475 M | 29.994 M | 34.756 M | 21.579 M | |
| Total Receivables | 115.711 M | 91.186 M | 109.964 M | 101.458 M | 141.308 M | 216.511 M | 260.522 M | 284.145 M | |
| Current Cash | 275.484 M | 286.805 M | 191.681 M | 128.089 M | 144.712 M | 131.077 M | 117.748 M | 259.775 M | |
| Total Non-current Assets | 99.219 M | 102.632 M | 99.613 M | 86.500 M | 84.107 M | 139.418 M | 153.973 M | 136.068 M | |
| Property Plant Equipment | 9.553 M | 9.571 M | 8.754 M | 7.724 M | 6.929 M | 6.069 M | 5.119 M | 4.188 M | |
| Other Assets | 86.103 M | 87.065 M | 84.928 M | 72.906 M | 71.369 M | 86.825 M | 77.181 M | 74.776 M | |
| Intangible Assets | 3.563 M | 5.996 M | 5.931 M | 5.870 M | 5.809 M | 46.524 M | 71.673 M | 57.104 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 546.003 M | 550.907 M | 480.847 M | 402.426 M | 469.591 M | 583.783 M | 629.604 M | 763.545 M | |
| Total liabilities | 568.632 M | 648.040 M | 618.265 M | 598.933 M | 644.355 M | 717.382 M | 823.029 M | 845.389 M | |
| Total current liabilities | 140.754 M | 171.319 M | 138.694 M | 123.407 M | 169.440 M | 239.659 M | 331.771 M | 538.303 M | |
| Accounts Payable | 17.486 M | 9.917 M | 11.526 M | 23.231 M | 29.278 M | 37.092 M | 35.219 M | 38.289 M | |
| Other liabilities | 102.000 K | 102.000 K | 3.467 M | 102.000 K | 102.000 K | 3.513 M | 11.459 M | 2.734 M | |
| Current long term debt | 0.000 | 0.000 | 1.191 M | 0.000 | 0.000 | 0.000 | 721.000 K | 175.000 M | |
| Long term debt | 420.965 M | 470.496 M | 472.476 M | 471.618 M | 472.191 M | 472.774 M | 473.720 M | 299.672 M | |
| Other liabilities | 102.000 K | 102.000 K | 3.467 M | 102.000 K | 102.000 K | 3.513 M | 11.459 M | 2.734 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -22.629 M | -97.133 M | -137.418 M | -196.507 M | -174.764 M | -133.599 M | -193.425 M | -81.844 M | |
| Common stock | 77.555 M | 77.747 M | 77.965 M | 79.269 M | 87.270 M | 97.739 M | 112.374 M | 112.749 M | |
| Retained earnings | -1.196 B | -1.283 B | -1.342 B | -1.417 B | -1.460 B | -1.500 B | -1.580 B | -1.477 B |